Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05867576
Other study ID # CH/2020/7042
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 12, 2021
Est. completion date March 30, 2024

Study information

Verified date February 2024
Source University Hospitals Bristol and Weston NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will assess the acceptability and feasibility of a randomised controlled trial of 6-12 sessions of remotely-delivered Acceptance and Commitment Therapy (ACT) versus waitlist control. Waitlist control will involve a delay in the offer of ACT sessions for 12 weeks. Participants may access all services as usual in this time. Follow-up assessments will be conducted at 12-, 24 and 48 weeks post-randomisation to measure effectiveness.


Description:

Tuberous Sclerosis Complex (TSC) is a genetic disease caused by mutations in the tumour suppressor genes TSC1 and TSC2. The clinical hallmarks of the disease are the growth of benign tumours in various organs such as the brain, kidneys and skin. Seizures are present in around 60% of the population and neurodevelopmental problems such as attention deficit disorder and autism are common. Anxiety and depressive disorders are similarly linked and at the psychosocial level, there is increasing evidence of the effect of TSC on self-esteem, family functioning and peer relationships resulting in poorer quality of life. Despite these difficulties, no unique treatments, and almost no effective evidenced psychological treatments for TSC are available. This trial aims to assess the feasibility and acceptability of Acceptance and Commitment Therapy (ACT) as a psychological treatment to improve quality of life among adolescents and young adults with TSC. ACT is a cognitive behavioural therapy that helps participants accept difficulties that they are unable to change. There is strong evidence for ACT's clinical effectiveness amongst patients with chronic diseases. The intervention will be delivered to participants aged 11-24 with TSC and sufficient cognitive and speech capabilities to take part. This will be delivered remotely via secure video-conferencing software. Our primary hypothesis is that ACT will be acceptable and feasible delivered remotely and may yield clinical improvements in health and quality of life. The study will be a 12-week, waitlist controlled randomised clinical trial. Participants will be randomised to receive 12-weeks treatment either immediately or following a 12-week wait. The treatment will be ACT adapted for 11-24-year olds who have TSC. Treatment will involve 6 to 12 weekly sessions of ACT of up to one hour each in length. Clinical outcomes will be assessed unblinded at baseline, 12, 24 and 48 weeks from randomisation. As a feasibility and acceptability study a range of physical and mental health outcomes are assessed. All clinical outcomes focus on health, wellbeing and quality of life from baseline to 12 week (3-month) follow-up amongst those offered ACT immediately versus waitlist controls.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date March 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender All
Age group 11 Years to 24 Years
Eligibility Inclusion Criteria: - Aged 11 to 24 years. - Diagnosis of Tuberous Sclerosis Complex. - Sufficient understanding of English to engage with the intervention (spoken and written), as judged by the assessing clinician. - Sufficient cognitive, sensory and speech capabilities to take part in the intervention. - Participants (or their parents if under 16) give verbal or written informed consent to participate in the study. - Participants give verbal or written assent if under 16. - Receiving treatment over video-conferencing will be the default modality for delivery, so access to the internet is a requirement. Exclusion Criteria: - Previous structured behavioural intervention within last 6 months. - Previous or current alcohol/substance dependence, psychosis, suicidality, or anorexia nervosa. - Moderate or severe intellectual disability. - Immediate risk to self or others. - Parent or child not able to speak, read or write English.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Acceptance and Commitment Therapy (ACT)
Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a "third wave" cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations.

Locations

Country Name City State
United Kingdom University Hospitals Bristol and Weston NHS Trust Bristol

Sponsors (3)

Lead Sponsor Collaborator
University Hospitals Bristol and Weston NHS Foundation Trust The Tuberous Sclerosis Association, University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment completion rate The proportion of patients showing interest who then consent to the trial and complete the intervention. Assessed at 3-month follow-up.
Primary Treatment completion rate The proportion of patients showing interest who then consent to the trial and complete the intervention. Assessed at 6-month follow-up
Primary Session attendance rate The session attendance rate compared to feasibility benchmarks. Assessed at 3-month follow-up
Primary Session attendance rate The session attendance rate compared to feasibility benchmarks. Assessed at 6-month follow-up
Primary The credibility/expectancy questionnaire Assessing participant ratings of treatment credibility. Minimum score = 5; maximum score = 45. Higher scores indicate better outcome. Assessed at baseline
Primary The credibility/expectancy questionnaire Assessing participant ratings of treatment credibility. Minimum score = 5; maximum score = 45. Higher scores indicate better outcome. Assessed at session 2
Primary The experience of service questionnaire A questionnaire used nationally in child and adolescent mental health services completed by patients and parents/carers (if under 16) to assess participants' experience of the intervention. An additional item has been added to the experience of service questionnaire to assess video-conferencing treatment satisfaction. Minimum score = 0; maximum score = 20. Higher scores indicate better outcome. Assessed at 3-month follow-up
Primary The experience of service questionnaire A questionnaire used nationally in child and adolescent mental health services completed by patients and parents/carers (if under 16) to assess participants' experience of the intervention. An additional item has been added to the experience of service questionnaire to assess video-conferencing treatment satisfaction. Minimum score = 0; maximum score = 20. Higher scores indicate better outcome. Assessed at 6-month follow-up
Secondary Acceptance and Action Questionnaire II A brief 7-item self-report measure assessing psychological inflexibility, which is the central treatment target for ACT. Validated for use among patients aged 16 and over. Minimum score = 7; maximum score = 49. Higher scores indicate worse outcome. Assessed at 3, 6 and 12-month follow-up.
Secondary Avoidance and Fusion Questionnaire for Youth 8-items A brief self-report measure of psychological inflexibility, for children (11 to 15 year old participants). Minimum score = 0; maximum score = 32. Higher scores indicate worse outcome. Assessed at 3, 6 and 12-month follow-up.
Secondary World Health Organisation wellbeing index 5-items A brief self-reported assessment of wellbeing and mental health. Minimum score = 7 score; maximum = 49. Higher scores indicate worse outcome. Minimum score = 0; maximum score = 49. Higher scores indicate worse outcome. Assessed at 3, 6 and 12-month follow-up.
Secondary Generalised Anxiety Disorder assessment 7-items A brief self-reported measure of generalised anxiety symptoms using 4-point Likert scales based on diagnostic criteria. Minimum score = 0; maximum score = 21. Higher scores indicate worse outcome. Assessed at 3, 6 and 12-month follow-up.
Secondary Patient Health Questionnaire 9-items Assesses symptoms of depression using self-reported 4-point Likert scales based on diagnostic criteria for major depression. Minimum score = 0; maximum score = 27. Higher scores indicate worse outcome. Assessed at 3, 6 and 12-month follow-up.
Secondary Client Service Receipt Inventory A research instrument developed to collect information on service receipt, service-related issues and income. In addition, the Client Service Receipt Inventory collects information on school attendance in the 3-months prior to assessment. Assessed at 3, 6 and 12-month follow-up.
Secondary TAND - TSC Associated Neuropsychiatric Disorders Assesses behavioural, intellectual, learning and psychiatric impact of TSC. Assessed at 3, 6 and 12-month follow-up.
Secondary Pediatric Quality of Life Inventory (PedsQL) A 23-item generic health status instrument with parent and child forms that assesses five domains of health (physical functioning, emotional functioning, psychosocial functioning, social functioning, and school functioning) in children and adolescents Assessed at 3, 6 and 12-month follow-up.
Secondary Experiential interviews Participant experiences of treatment as described in semi-structured qualitative interviews Assessed at 3- and 6-month follow-up
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02687633 - Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex N/A
Completed NCT02201212 - Everolimus for Cancer With TSC1 or TSC2 Mutation Phase 2
Completed NCT01767779 - Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
Recruiting NCT05104983 - Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Phase 2
Recruiting NCT02098759 - Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex N/A
Recruiting NCT01730209 - Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase 2/Phase 3
Recruiting NCT03356769 - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Phase 2
Recruiting NCT04987463 - Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Phase 2/Phase 3
Completed NCT05323370 - Lymphangioleiomyomatosis, a Study on Cathepsin K
Recruiting NCT06392009 - A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II Phase 1/Phase 2
Enrolling by invitation NCT05604170 - Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy Phase 3
Completed NCT03276195 - Studies in Patients With Tuberous Sclerosis Complex
Recruiting NCT05059327 - Basimglurant in Children, Adolescents, and Young Adults With TSC Phase 2
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Active, not recruiting NCT04112537 - Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Active, not recruiting NCT02962414 - Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Phase 3
Active, not recruiting NCT05495425 - Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC Phase 3
Active, not recruiting NCT05044819 - Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Phase 4
Completed NCT01929642 - Rapalogues for Autism Phenotype in TSC: A Feasibility Study Phase 2